Myeloid cell–mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference

Blood Neoplasia · Published 2026-05-05 · DOI 10.1016/j.bneo.2026.100242

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.bneo.2026.100242

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Somatic UBA1 mutations in pediatric MDS/AML: first cases suggest distinct pathogenesis from adult VEXAS syndrome · Blood Neoplasia · 2026 · Same journal
• Clinical features and outcomes of MPN with concurrent MPL and JAK2/CALR Mutations · Blood Neoplasia · 2026 · Same journal
• Timing of response in patients with relapsed/refractory FLT3mut+ acute myeloid leukemia treated with gilteritinib · Blood Neoplasia · 2026 · Same journal
• Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report · Blood Neoplasia · 2026 · Same journal
• CD8+CD38+ T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlates · Blood Neoplasia · 2026 · Same journal
• Abnormal serum immunofixation patterns are common after BCMA CAR-T in multiple myeloma and are preceded by immune events · Blood Neoplasia · 2026 · Same journal
• Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report · Blood Neoplasia · 2026 · Same journal
• Deletion 11q, monosomy 13, and deletion 13q in noncomplex karyotype acute myeloid leukemia · Blood Neoplasia · 2026 · Same journal
• Homozygosity of germ line JAK2 46/1 haplotype contributes to phenotype and outcome diversity in polycythemia vera · Blood Neoplasia · 2026 · Same journal
• Favezelimab plus pembrolizumab for anti–PD-1–refractory classic Hodgkin lymphoma: an open-label phase 1/2 study · Blood Neoplasia · 2026 · Same journal